数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Ronald D. Green 男 Director 65 31.75万美元 1.87 2026-10-01
Ralph A. Rodriguez 男 Director 59 31.56万美元 2.08 2026-10-01
Catherine E. Woteki 女 Director 78 31.75万美元 1.91 2026-10-01
Aashima Gupta 女 Director 55 31.00万美元 2.78 2026-10-01
Andrea F. Wainer 女 Director 57 38.18万美元 0.20 2026-10-01
Andrea F. Wainer -- Director 58 未披露 未持股 2026-10-01
Raphael A. Rodriguez 男 Director 58 未披露 未持股 2026-10-01
Mike Nassif 男 Chief Executive Officer and Director and President 50 869.39万美元 51.94 2026-10-01
James C. Borel 男 Chairman of the Board and Director 70 36.75万美元 9.63 2026-10-01
Jeffrey D. Capello 男 Director 61 34.50万美元 3.25 2026-10-01
Avi Pelossof 男 Director 63 28.72万美元 未持股 2026-10-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
R. Bryan Riggsbee 男 Chief Financial Officer and Senior Vice President 55 333.91万美元 未持股 2026-10-01
Tamara A. Ranalli 女 General Manager, Global Food Safety and Senior Vice President 53 214.89万美元 未持股 2026-10-01
Mike Nassif 男 Chief Executive Officer and Director and President 50 869.39万美元 51.94 2026-10-01
Tamara A. Ranalli 女 General Manager, Global Food Safety and Senior Vice President 54 未披露 未持股 2026-10-01
R. Bryan Riggsbee 男 Chief Financial Officer and Senior Vice President 55 未披露 未持股 2026-10-01
Jennifer Evans Stacey 女 Chief Legal and Compliance Officer, Secretary and Senior Vice President 61 81.50万美元 未持股 2026-10-01

董事简历

中英对照 |  中文 |  英文
Ronald D. Green

Ronald D. Green,他是农业和自然资源学院(the Institute of Agriculture and Natural Resources)的哈伦副总会计师,以及内布拉斯加州大学(University of Nebraska)系统的农业与天然资源的副总裁。他曾担任Pfizer Animal Health公司的动物基因组学企业的负责技术服务的高级全球董事(从2008年到2010年)。他也曾任教于德州理工大学(Texas Tech University)和科罗拉多州立大学(Colorado State),也曾担任美国农业部农业研究服务局(the USDA’s Agricultural Research Service)的动物生产研究的国家项目领导人,以及白宫跨部门的动物基因组学的工作集团和国家科学技术委员会(the National Science and Technology Council)的执行秘书。他是国际牛、猪和绵羊的基因组测序项目领导人。他是the American Society of Animal Science(ASAS)、the National Block and Bridle Club的前任总裁,也曾担任the U.S. Beef Improvement Federation、National Cattlemen’s Beef Association、National Pork Board、Federated Animal Science Societies、the National Research Council的多种领导职务。他于2014年被任命为ASAS公司的会员。


Ronald D. Green Chancellor Emeritus of the University of Nebraska Lincoln, has over 40 years of leadership in agricultural and food sciences. At UNL, he managed a $1.3B budget and 6,500 employees, and previously served as Vice Chancellor of the Institute of Agriculture and Natural Resources.
Ronald D. Green,他是农业和自然资源学院(the Institute of Agriculture and Natural Resources)的哈伦副总会计师,以及内布拉斯加州大学(University of Nebraska)系统的农业与天然资源的副总裁。他曾担任Pfizer Animal Health公司的动物基因组学企业的负责技术服务的高级全球董事(从2008年到2010年)。他也曾任教于德州理工大学(Texas Tech University)和科罗拉多州立大学(Colorado State),也曾担任美国农业部农业研究服务局(the USDA’s Agricultural Research Service)的动物生产研究的国家项目领导人,以及白宫跨部门的动物基因组学的工作集团和国家科学技术委员会(the National Science and Technology Council)的执行秘书。他是国际牛、猪和绵羊的基因组测序项目领导人。他是the American Society of Animal Science(ASAS)、the National Block and Bridle Club的前任总裁,也曾担任the U.S. Beef Improvement Federation、National Cattlemen’s Beef Association、National Pork Board、Federated Animal Science Societies、the National Research Council的多种领导职务。他于2014年被任命为ASAS公司的会员。
Ronald D. Green Chancellor Emeritus of the University of Nebraska Lincoln, has over 40 years of leadership in agricultural and food sciences. At UNL, he managed a $1.3B budget and 6,500 employees, and previously served as Vice Chancellor of the Institute of Agriculture and Natural Resources.
Ralph A. Rodriguez

Ralph A.Rodriguez目前是总部位于马萨诸塞州波士顿的全球私募股权公司Summit Partners的常驻高管。Rodriguez先生与Summit’;的技术团队合作,在处于成长期的技术公司中发现新的投资机会。在2019年10月加入Summit之前,他是Facebook的研究科学家,在那里他领导应用身份和智能。从2015年到2018年,他是ID认证公司Confirm.io的联合创始人兼首席技术官,Facebook于2018年3月收购了该公司。在确认.io之前,Rodriguez先生创立了:Blue Hill Research,一家全球IT市场研究公司;网络安全公司Delfigo Security和Invenio;和NTA,一家专利、版权和商标许可和研究公司。他也曾担任Brooks Automation、C-Bridge Internet Solutions和Excelon Corporation的上市公司首席技术官/首席信息官。作为麻省理工学院(MIT Institute of Technology)任职时间最长的ASP研究员,他在麻省理工学院媒体实验室和哈佛-麻省理工学院(Harvard-MIT)健康科学和技术部门率先开展了人工智能、云、移动、神经科学和安全技术的研究。他目前在Corvium和Strategic Cyber Ventures的董事会任职。此前,他曾担任应用科学研究院、Veramark Technologies和技术费用管理行业协会的董事。


Ralph A. Rodriguez,has been President & Chief Product Officer and a member of the board of directors of Daon, Inc., an international biometric and identity assurance software company, since June 2022. Prior to this role, he was executive-in-residence from October 2019 through June 2022 at Summit Partners, a global private equity firm based in Boston. Mr. Rodriguez worked with Summit's technology team to identify new investment opportunities within growth-stage technology companies. Prior to that, he was a research scientist at Facebook from March 2018 through October 2019, where he led Applied Identity and Intelligence. He was the co-founder, in 2015, and CTO of Confirm.io, an ID authentication company, which Facebook acquired in March 2018. Prior to Confirm.io, Mr. Rodriguez was an executive with a number of notable technology companies, and is the founder of several technology companies. He is the longest-serving ASP Fellow at the Massachusetts Institute of Technology, and currently also serves on the board of Strategic Cyber Ventures. Mr. Rodriguez previously served on the board of Corvium. Mr. Rodriguez is a U.S. Army intelligence veteran of the Persian Gulf War, a life member of the Veterans of Foreign Wars, and a holder of 23 U.S. patents and international patent applications.
Ralph A.Rodriguez目前是总部位于马萨诸塞州波士顿的全球私募股权公司Summit Partners的常驻高管。Rodriguez先生与Summit’;的技术团队合作,在处于成长期的技术公司中发现新的投资机会。在2019年10月加入Summit之前,他是Facebook的研究科学家,在那里他领导应用身份和智能。从2015年到2018年,他是ID认证公司Confirm.io的联合创始人兼首席技术官,Facebook于2018年3月收购了该公司。在确认.io之前,Rodriguez先生创立了:Blue Hill Research,一家全球IT市场研究公司;网络安全公司Delfigo Security和Invenio;和NTA,一家专利、版权和商标许可和研究公司。他也曾担任Brooks Automation、C-Bridge Internet Solutions和Excelon Corporation的上市公司首席技术官/首席信息官。作为麻省理工学院(MIT Institute of Technology)任职时间最长的ASP研究员,他在麻省理工学院媒体实验室和哈佛-麻省理工学院(Harvard-MIT)健康科学和技术部门率先开展了人工智能、云、移动、神经科学和安全技术的研究。他目前在Corvium和Strategic Cyber Ventures的董事会任职。此前,他曾担任应用科学研究院、Veramark Technologies和技术费用管理行业协会的董事。
Ralph A. Rodriguez,has been President & Chief Product Officer and a member of the board of directors of Daon, Inc., an international biometric and identity assurance software company, since June 2022. Prior to this role, he was executive-in-residence from October 2019 through June 2022 at Summit Partners, a global private equity firm based in Boston. Mr. Rodriguez worked with Summit's technology team to identify new investment opportunities within growth-stage technology companies. Prior to that, he was a research scientist at Facebook from March 2018 through October 2019, where he led Applied Identity and Intelligence. He was the co-founder, in 2015, and CTO of Confirm.io, an ID authentication company, which Facebook acquired in March 2018. Prior to Confirm.io, Mr. Rodriguez was an executive with a number of notable technology companies, and is the founder of several technology companies. He is the longest-serving ASP Fellow at the Massachusetts Institute of Technology, and currently also serves on the board of Strategic Cyber Ventures. Mr. Rodriguez previously served on the board of Corvium. Mr. Rodriguez is a U.S. Army intelligence veteran of the Persian Gulf War, a life member of the Veterans of Foreign Wars, and a holder of 23 U.S. patents and international patent applications.
Catherine E. Woteki

Catherine E. Woteki是爱荷华州立大学农业与生命科学学院的前任院长,也是弗吉尼亚大学生物复杂性研究所的客座特聘研究员。她此前曾担任美国农业部首席科学家、研究、教育和经济部副部长(2010 – 2016年)、Mars,Inc.科学和监管事务全球总监,以及美国农业部首任食品安全副部长。


Catherine E. Woteki is Former Dean of the College of Agriculture and Life Sciences at Iowa State University and Visiting Distinguished Fellow at the University of Virginia's Biocomplexity Institute. She previously served as USDA Chief Scientist and Under Secretary for Research, Education, and Economics (2010–2016), Global Director of Scientific and Regulatory Affairs at Mars, Inc., and USDA's first Under Secretary for Food Safety.
Catherine E. Woteki是爱荷华州立大学农业与生命科学学院的前任院长,也是弗吉尼亚大学生物复杂性研究所的客座特聘研究员。她此前曾担任美国农业部首席科学家、研究、教育和经济部副部长(2010 – 2016年)、Mars,Inc.科学和监管事务全球总监,以及美国农业部首任食品安全副部长。
Catherine E. Woteki is Former Dean of the College of Agriculture and Life Sciences at Iowa State University and Visiting Distinguished Fellow at the University of Virginia's Biocomplexity Institute. She previously served as USDA Chief Scientist and Under Secretary for Research, Education, and Economics (2010–2016), Global Director of Scientific and Regulatory Affairs at Mars, Inc., and USDA's first Under Secretary for Food Safety.
Aashima Gupta

Aashima Gupta在通过技术转型推动业务增长、差异化和改善方面拥有超过25年的经验。目前,Gupta女士在Google Cloud担任医疗垂直领域的全球总监,在那里她领导跨提供者和付款人的GenAI战略,在行业需求和新技术的动态交叉中导航。在加入Google之前,Gupta女士曾在多个组织从事技术开发工作,包括NIIT、Fidelity Investments、J.P. Morgan Chase、Apigee和Kaiser Permanente。她的经验涉及相关细分市场、技术、地域和业务职能。除了强大的技术和领导能力,她还拥有两项计算机应用专利。


Aashima Gupta has over 25 years of experience in driving business growth, differentiation, and improvement through technology transformation. Currently, Ms. Gupta serves as Global Director for the healthcare vertical at Google Cloud, where she leads the GenAI strategy across Providers and Payers, navigating the dynamic intersection of industry needs and new technologies.Prior to joining Google, Ms. Gupta worked in technology development across a number of organizations, including NIIT, Fidelity Investments, J.P. Morgan Chase, Apigee, and Kaiser Permanente. Her experience spans relevant market segments, technologies, geographies, and business functions. In addition to her strong technical and leadership skills, she holds two patents in computer applications.
Aashima Gupta在通过技术转型推动业务增长、差异化和改善方面拥有超过25年的经验。目前,Gupta女士在Google Cloud担任医疗垂直领域的全球总监,在那里她领导跨提供者和付款人的GenAI战略,在行业需求和新技术的动态交叉中导航。在加入Google之前,Gupta女士曾在多个组织从事技术开发工作,包括NIIT、Fidelity Investments、J.P. Morgan Chase、Apigee和Kaiser Permanente。她的经验涉及相关细分市场、技术、地域和业务职能。除了强大的技术和领导能力,她还拥有两项计算机应用专利。
Aashima Gupta has over 25 years of experience in driving business growth, differentiation, and improvement through technology transformation. Currently, Ms. Gupta serves as Global Director for the healthcare vertical at Google Cloud, where she leads the GenAI strategy across Providers and Payers, navigating the dynamic intersection of industry needs and new technologies.Prior to joining Google, Ms. Gupta worked in technology development across a number of organizations, including NIIT, Fidelity Investments, J.P. Morgan Chase, Apigee, and Kaiser Permanente. Her experience spans relevant market segments, technologies, geographies, and business functions. In addition to her strong technical and leadership skills, she holds two patents in computer applications.
Andrea F. Wainer

Andrea F. Wainer,自2019年起在医疗器械和健康护理公司雅培(Abbott)担任快速和分子诊断执行副总裁。在雅培近22年的时间里,Wainer女士担任的职务越来越重要,包括2015年至2019年担任Abbott Molecular Diagnostics总裁,2011年至2014年担任Abbott 动物保健国际总裁,2009年至2011年担任Abbott Renal Care部门副总裁/总经理。Wainer女士担任古德曼剧院董事会成员。


Andrea F. Wainer served as Executive Vice President, Rapid and Molecular Diagnostics at Abbott Laboratories (Abbott), a medical devices and health care company, from 2019 to February 2025. During her nearly 22 years at Abbott, Ms. Wainer served in roles of increasing responsibility including as President, Abbott Molecular Diagnostics, from 2015 to 2019, President, Abbott Animal Health, from 2011 to 2014, and Divisional Vice President/General Manager, Abbott Renal Care, from 2009 to 2011. Ms. Wainer serves as a member of the Board of Trtees of the Goodman Theatre.
Andrea F. Wainer,自2019年起在医疗器械和健康护理公司雅培(Abbott)担任快速和分子诊断执行副总裁。在雅培近22年的时间里,Wainer女士担任的职务越来越重要,包括2015年至2019年担任Abbott Molecular Diagnostics总裁,2011年至2014年担任Abbott 动物保健国际总裁,2009年至2011年担任Abbott Renal Care部门副总裁/总经理。Wainer女士担任古德曼剧院董事会成员。
Andrea F. Wainer served as Executive Vice President, Rapid and Molecular Diagnostics at Abbott Laboratories (Abbott), a medical devices and health care company, from 2019 to February 2025. During her nearly 22 years at Abbott, Ms. Wainer served in roles of increasing responsibility including as President, Abbott Molecular Diagnostics, from 2015 to 2019, President, Abbott Animal Health, from 2011 to 2014, and Divisional Vice President/General Manager, Abbott Renal Care, from 2009 to 2011. Ms. Wainer serves as a member of the Board of Trtees of the Goodman Theatre.
Andrea F. Wainer

Andrea F. Wainer拥有Neogen董事会近30年的诊断和医疗保健经验。最近,她担任雅培快速和分子诊断领域的执行副总裁,在那里她领导了三项全球业务,涵盖分子诊断、快速即时检测和手持诊断设备。


Andrea F. Wainer has nearly 30 years of diagnostics and healthcare experience to Neogen's Board of Directors. Most recently, she was Executive Vice President of Rapid and Molecular Diagnostics at Abbott Laboratories, where she led three global businesses spanning molecular diagnostics, rapid point of care testing, and handheld diagnostic devices.
Andrea F. Wainer拥有Neogen董事会近30年的诊断和医疗保健经验。最近,她担任雅培快速和分子诊断领域的执行副总裁,在那里她领导了三项全球业务,涵盖分子诊断、快速即时检测和手持诊断设备。
Andrea F. Wainer has nearly 30 years of diagnostics and healthcare experience to Neogen's Board of Directors. Most recently, she was Executive Vice President of Rapid and Molecular Diagnostics at Abbott Laboratories, where she led three global businesses spanning molecular diagnostics, rapid point of care testing, and handheld diagnostic devices.
Raphael A. Rodriguez

Raphael A. Rodriguez自2022年起担任全球生物识别和身份保证公司Daon,Inc.的总裁、首席产品官和董事。Rodriguez先生此前曾担任Summit Partners的常驻主管、Facebook Leading Applied Identity and Intelligence的研究科学家,以及Confirm.io的联合创始人/CTO,Confirm.io于2018年被Facebook收购。


Raphael A. Rodriguez has been President, Chief Product Officer, and a Director of Daon, Inc., a global biometric and identity assurance company, since 2022. Mr. Rodriguez previously served as Executive in Residence at Summit Partners, Research Scientist at Facebook leading Applied Identity and Intelligence, and co founder/CTO of Confirm.io, acquired by Facebook in 2018.
Raphael A. Rodriguez自2022年起担任全球生物识别和身份保证公司Daon,Inc.的总裁、首席产品官和董事。Rodriguez先生此前曾担任Summit Partners的常驻主管、Facebook Leading Applied Identity and Intelligence的研究科学家,以及Confirm.io的联合创始人/CTO,Confirm.io于2018年被Facebook收购。
Raphael A. Rodriguez has been President, Chief Product Officer, and a Director of Daon, Inc., a global biometric and identity assurance company, since 2022. Mr. Rodriguez previously served as Executive in Residence at Summit Partners, Research Scientist at Facebook leading Applied Identity and Intelligence, and co founder/CTO of Confirm.io, acquired by Facebook in 2018.
Mike Nassif

Mike Nassif于2025年8月11日加入Neogen,担任总裁兼首席执行官。他从Siemens Healthineers加入公司,自2022年9月起担任Point of Care Diagnostics全球总裁。在任职Siemens Healthineers之前,Nassif先生曾在百特国际有限公司(2017年3月至2022年9月)、百威英博(2015年4月至2017年3月)和强生(2009年5月至2015年4月)担任多个领导职务。


Mike Nassif joined Neogen on August 11, 2025 as President & Chief Executive Officer. He joined the Company from Siemens Healthineers, where he served as Global President of the Point of Care Diagnostics since September 2022. Prior to his time at Siemens Healthineers, Mr. Nassif served in various leadership positions at Baxter International Inc. (March 2017 to September 2022), Anheuser Busch InBev (April 2015 to March 2017), and Johnson & Johnson (May 2009 to April 2015).
Mike Nassif于2025年8月11日加入Neogen,担任总裁兼首席执行官。他从Siemens Healthineers加入公司,自2022年9月起担任Point of Care Diagnostics全球总裁。在任职Siemens Healthineers之前,Nassif先生曾在百特国际有限公司(2017年3月至2022年9月)、百威英博(2015年4月至2017年3月)和强生(2009年5月至2015年4月)担任多个领导职务。
Mike Nassif joined Neogen on August 11, 2025 as President & Chief Executive Officer. He joined the Company from Siemens Healthineers, where he served as Global President of the Point of Care Diagnostics since September 2022. Prior to his time at Siemens Healthineers, Mr. Nassif served in various leadership positions at Baxter International Inc. (March 2017 to September 2022), Anheuser Busch InBev (April 2015 to March 2017), and Johnson & Johnson (May 2009 to April 2015).
James C. Borel

James C. Borel,他于1978年加入DuPont公司,担任Agricultural Products公司的产品和销售管理职位。他于1993年搬到日本东京,任职Agricultural Products公司,担任北亚洲区域经理,并于1994年被任命为亚太地区区域主任。他于1997年被任命为北美区域董事,此后并被任命副总裁和总经理,负责杜邦农作物保护。他于2004年1月被任命为高级副总裁,负责杜邦公司全球人力资源。他于2008年成为集团副总裁,并于2009年10月被任命为执行副总裁,负责杜邦作物保护和先锋。他于2011年负责杜邦营养与健康,并于2014年负责公司的可持续发展。


James C. Borel currently serves as Chair of the Board. He retired in 2016 from DuPont, where he was Executive Vice President with responsibility for their agricultural and food ingredients businesses, as well as the corporate functions of Sustainability and Government Affairs.
James C. Borel,他于1978年加入DuPont公司,担任Agricultural Products公司的产品和销售管理职位。他于1993年搬到日本东京,任职Agricultural Products公司,担任北亚洲区域经理,并于1994年被任命为亚太地区区域主任。他于1997年被任命为北美区域董事,此后并被任命副总裁和总经理,负责杜邦农作物保护。他于2004年1月被任命为高级副总裁,负责杜邦公司全球人力资源。他于2008年成为集团副总裁,并于2009年10月被任命为执行副总裁,负责杜邦作物保护和先锋。他于2011年负责杜邦营养与健康,并于2014年负责公司的可持续发展。
James C. Borel currently serves as Chair of the Board. He retired in 2016 from DuPont, where he was Executive Vice President with responsibility for their agricultural and food ingredients businesses, as well as the corporate functions of Sustainability and Government Affairs.
Jeffrey D. Capello

Jeffrey D. Capello,2012年3月起担任Biogen Inc.董事。他现为医疗器械公司Boston Scientific Corporation的高级顾问。他于2008年6月加入Boston Scientific Corporation,担任高级副总裁、首席会计官,直到2010年3月;2010年3月至2013年12月,担任执行副总裁、首席财务官。之前,2006年至2008年6月,他担任科技公司PerkinElmer的高级副总裁、首席财务官,负责业务开发;此前,2002-2006,他担任其财务副总裁、企业财务总监、财务总管;2001-2005,担任财务副总裁、企业财务总监、首席会计官、财务总管。1991-2001,他在会计师事务所PricewaterhouseCoopers LLP担任过多个职务,其中包括1997-2001年间,担任合伙人。他从2008年1月起,担任Sirtris Pharmaceuticals的董事,直到2008年6月该公司被收购,也曾担任审核委员会的成员和主席。他获得了Vermont大学的工商管理学士学位、 Harvard Business School的工商管理硕士学位。他是注册会计师。


Jeffrey D. Capello is a senior finance executive with over 30 years of experience and is currently Managing Partner at Monomoy Advisors, LLC advising leadership on shareholder value creation strategies. He previously served as CFO of several public and private equity backed companies, including PerkinElmer, Boston Scientific, Ortho Clinical Diagnostics, Beacon Health Options, and Biogen.
Jeffrey D. Capello,2012年3月起担任Biogen Inc.董事。他现为医疗器械公司Boston Scientific Corporation的高级顾问。他于2008年6月加入Boston Scientific Corporation,担任高级副总裁、首席会计官,直到2010年3月;2010年3月至2013年12月,担任执行副总裁、首席财务官。之前,2006年至2008年6月,他担任科技公司PerkinElmer的高级副总裁、首席财务官,负责业务开发;此前,2002-2006,他担任其财务副总裁、企业财务总监、财务总管;2001-2005,担任财务副总裁、企业财务总监、首席会计官、财务总管。1991-2001,他在会计师事务所PricewaterhouseCoopers LLP担任过多个职务,其中包括1997-2001年间,担任合伙人。他从2008年1月起,担任Sirtris Pharmaceuticals的董事,直到2008年6月该公司被收购,也曾担任审核委员会的成员和主席。他获得了Vermont大学的工商管理学士学位、 Harvard Business School的工商管理硕士学位。他是注册会计师。
Jeffrey D. Capello is a senior finance executive with over 30 years of experience and is currently Managing Partner at Monomoy Advisors, LLC advising leadership on shareholder value creation strategies. He previously served as CFO of several public and private equity backed companies, including PerkinElmer, Boston Scientific, Ortho Clinical Diagnostics, Beacon Health Options, and Biogen.
Avi Pelossof

Avi Pelossof,2008年2月至2013年2月担任传染病事业部的副总裁后,他被任命为传染病的事业部全球总裁直到2013年3月。他于2007年1月加入公司,担任血源性病原体的副总裁,并担任该角色直到2008年1月。他在诊断,全球健康和国际金融行业有超过20年的丰富工作经验,包括担任远化学诊断系统公司(为传染病的诊断测试的制造商)高级职务,以及花旗集团。


Avi Pelossof was appointed Global President of infectious disease business unit in March 2013 after serving as Vice President of infectious disease business unit from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008.
Avi Pelossof,2008年2月至2013年2月担任传染病事业部的副总裁后,他被任命为传染病的事业部全球总裁直到2013年3月。他于2007年1月加入公司,担任血源性病原体的副总裁,并担任该角色直到2008年1月。他在诊断,全球健康和国际金融行业有超过20年的丰富工作经验,包括担任远化学诊断系统公司(为传染病的诊断测试的制造商)高级职务,以及花旗集团。
Avi Pelossof was appointed Global President of infectious disease business unit in March 2013 after serving as Vice President of infectious disease business unit from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008.

高管简历

中英对照 |  中文 |  英文
R. Bryan Riggsbee

R. Bryan Riggsbee,首席财务官,于2014年10月加入本公司。此前,他在Laboratory Corporation of America LabCorp工作了10年,最后的是企业财务高级副总裁,负责财务规划与分析、司库工作。加入 LabCorp之前,他在General Electric担任过各种财务职位,在KPMG的审计部门开启职业生涯。他在North Carolina State University获得会计学士学位,在University of North Carolina at Chapel Hill获得政治学士学位,在Northwestern University获得工商管理硕士学位。他是北卡罗莱纳州的注册会计师。


R. Bryan Riggsbee previously served 10 years with Laboratory Corporation of America LabCorp where his most recent position was as Senior Vice President of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.
R. Bryan Riggsbee,首席财务官,于2014年10月加入本公司。此前,他在Laboratory Corporation of America LabCorp工作了10年,最后的是企业财务高级副总裁,负责财务规划与分析、司库工作。加入 LabCorp之前,他在General Electric担任过各种财务职位,在KPMG的审计部门开启职业生涯。他在North Carolina State University获得会计学士学位,在University of North Carolina at Chapel Hill获得政治学士学位,在Northwestern University获得工商管理硕士学位。他是北卡罗莱纳州的注册会计师。
R. Bryan Riggsbee previously served 10 years with Laboratory Corporation of America LabCorp where his most recent position was as Senior Vice President of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.
Tamara A. Ranalli

Tamara A. Ranalli,2020年8月成为分子事业部高级副总裁。在担任Quidel这一职位之前,Ranalli博士曾在Quidel担任过多个职务,最近担任北美市场营销副总裁,自2010年以来一直在该组织工作。Ranalli博士拥有康奈尔大学生物学学士学位、罗切斯特大学医学院生物化学博士学位,并在Roswell Park癌症研究所完成了癌症遗传学的博士后研究。


Tamara A. Ranalli, became the Senior Vice President, Molecular Business Unit in August 2020. Prior to this position at Quidel, Dr. Ranalli held several roles at Quidel most recently as Vice President of Marketing for North America and has been with the organization since 2010.Dr. Ranalli holds a B.A. degree in Biology from Cornell University, a Ph.D. in Biochemistry from University of Rochester School of Medicine and completed a post-doctoral fellowship in Cancer Genetics at Roswell Park Cancer Institute.
Tamara A. Ranalli,2020年8月成为分子事业部高级副总裁。在担任Quidel这一职位之前,Ranalli博士曾在Quidel担任过多个职务,最近担任北美市场营销副总裁,自2010年以来一直在该组织工作。Ranalli博士拥有康奈尔大学生物学学士学位、罗切斯特大学医学院生物化学博士学位,并在Roswell Park癌症研究所完成了癌症遗传学的博士后研究。
Tamara A. Ranalli, became the Senior Vice President, Molecular Business Unit in August 2020. Prior to this position at Quidel, Dr. Ranalli held several roles at Quidel most recently as Vice President of Marketing for North America and has been with the organization since 2010.Dr. Ranalli holds a B.A. degree in Biology from Cornell University, a Ph.D. in Biochemistry from University of Rochester School of Medicine and completed a post-doctoral fellowship in Cancer Genetics at Roswell Park Cancer Institute.
Mike Nassif

Mike Nassif于2025年8月11日加入Neogen,担任总裁兼首席执行官。他从Siemens Healthineers加入公司,自2022年9月起担任Point of Care Diagnostics全球总裁。在任职Siemens Healthineers之前,Nassif先生曾在百特国际有限公司(2017年3月至2022年9月)、百威英博(2015年4月至2017年3月)和强生(2009年5月至2015年4月)担任多个领导职务。


Mike Nassif joined Neogen on August 11, 2025 as President & Chief Executive Officer. He joined the Company from Siemens Healthineers, where he served as Global President of the Point of Care Diagnostics since September 2022. Prior to his time at Siemens Healthineers, Mr. Nassif served in various leadership positions at Baxter International Inc. (March 2017 to September 2022), Anheuser Busch InBev (April 2015 to March 2017), and Johnson & Johnson (May 2009 to April 2015).
Mike Nassif于2025年8月11日加入Neogen,担任总裁兼首席执行官。他从Siemens Healthineers加入公司,自2022年9月起担任Point of Care Diagnostics全球总裁。在任职Siemens Healthineers之前,Nassif先生曾在百特国际有限公司(2017年3月至2022年9月)、百威英博(2015年4月至2017年3月)和强生(2009年5月至2015年4月)担任多个领导职务。
Mike Nassif joined Neogen on August 11, 2025 as President & Chief Executive Officer. He joined the Company from Siemens Healthineers, where he served as Global President of the Point of Care Diagnostics since September 2022. Prior to his time at Siemens Healthineers, Mr. Nassif served in various leadership positions at Baxter International Inc. (March 2017 to September 2022), Anheuser Busch InBev (April 2015 to March 2017), and Johnson & Johnson (May 2009 to April 2015).
Tamara A. Ranalli

Tamara A. Ranalli于2026年1月7日加入Neogen,担任全球食品安全高级副总裁兼总经理。Ranalli博士全面负责Neogen全球食品安全产品组合的损益,制定和执行持续创新和增长的全球战略,包括营销、研发以及政府和监管事务。在加入Neogen之前,Ranalli博士于2024年至2025年在QuidelOrtho担任高级副总裁兼分子诊断和即时护理业务部门总经理,并于2020年至2024年担任分子诊断业务部门高级副总裁。在QuidelOrtho任职期间,Ranalli博士担任的职务越来越重要,她领导着公司诊断产品组合内的全球业务、产品开发、监管和商业活动。


Tamara A. Ranalli joined Neogen on January 7, 2026 as Senior Vice President and General Manager, Global Food Safety. Dr. Ranalli has full P&L responsibility for Neogen's global Food Safety portfolio, developing and executing the global strategy for continued innovation and growth, including marketing, research and development, and government and regulatory affairs. Prior to joining Neogen, Dr. Ranalli served as Senior Vice President and General Manager, Molecular Diagnostics and Point of Care Business Units, at QuidelOrtho from 2024 to 2025, and as Senior Vice President, Molecular Diagnostics Business Unit, from 2020 to 2024. During her tenure at QuidelOrtho, Dr. Ranalli held positions of increasing responsibility leading global business, product development, regulatory, and commercial activities within the company's diagnostics portfolio.
Tamara A. Ranalli于2026年1月7日加入Neogen,担任全球食品安全高级副总裁兼总经理。Ranalli博士全面负责Neogen全球食品安全产品组合的损益,制定和执行持续创新和增长的全球战略,包括营销、研发以及政府和监管事务。在加入Neogen之前,Ranalli博士于2024年至2025年在QuidelOrtho担任高级副总裁兼分子诊断和即时护理业务部门总经理,并于2020年至2024年担任分子诊断业务部门高级副总裁。在QuidelOrtho任职期间,Ranalli博士担任的职务越来越重要,她领导着公司诊断产品组合内的全球业务、产品开发、监管和商业活动。
Tamara A. Ranalli joined Neogen on January 7, 2026 as Senior Vice President and General Manager, Global Food Safety. Dr. Ranalli has full P&L responsibility for Neogen's global Food Safety portfolio, developing and executing the global strategy for continued innovation and growth, including marketing, research and development, and government and regulatory affairs. Prior to joining Neogen, Dr. Ranalli served as Senior Vice President and General Manager, Molecular Diagnostics and Point of Care Business Units, at QuidelOrtho from 2024 to 2025, and as Senior Vice President, Molecular Diagnostics Business Unit, from 2020 to 2024. During her tenure at QuidelOrtho, Dr. Ranalli held positions of increasing responsibility leading global business, product development, regulatory, and commercial activities within the company's diagnostics portfolio.
R. Bryan Riggsbee

R. Bryan Riggsbee于2025年11月3日加入Neogen,担任高级副总裁兼首席财务官。Riggsbee先生负责监管Neogen的全球金融组织。在加入Neogen之前,Riggsbee先生于2025年担任生物梅里埃北美业务的首席财务官,负责支持公司在该地区诊断业务的财务组织。从2014年到2024年,Riggsbee先生担任执行副总裁、Myriad Genetics, Inc.以及TERM1 Genetics,Inc.的财务主管。Riggsbee先生目前担任CareDx,Inc.的独立董事(自2024年起)并担任审计和财务委员会主席;担任Immunovia AB的独立董事(自2025年起)并在审计和薪酬委员会任职。在其职业生涯的早期,Riggsbee先生曾在美国实验室公司、通用电气公司和毕马威会计师事务所担任财务领导职务。


R. Bryan Riggsbee joined Neogen on November 3, 2025 as Senior Vice President & Chief Financial Officer. Mr. Riggsbee oversees Neogen's global finance organization. Prior to joining Neogen, Mr. Riggsbee served as Chief Financial Officer of bioMérieux's North American business in 2025, where he was responsible for the finance organization supporting the company's diagnostics operations in the region. From 2014 to 2024, Mr. Riggsbee served as Executive Vice President, Chief Financial Officer and Treasurer of Myriad Genetics, Inc. Mr. Riggsbee currently serves as an independent director of CareDx, Inc. (since 2024), where he chairs the Audit and Finance Committee, and as an independent director of Immunovia AB (since 2025), where he serves on the Audit and Remuneration Committees. Earlier in his career, Mr. Riggsbee held finance leadership roles with Laboratory Corporation of America, GE, and KPMG.
R. Bryan Riggsbee于2025年11月3日加入Neogen,担任高级副总裁兼首席财务官。Riggsbee先生负责监管Neogen的全球金融组织。在加入Neogen之前,Riggsbee先生于2025年担任生物梅里埃北美业务的首席财务官,负责支持公司在该地区诊断业务的财务组织。从2014年到2024年,Riggsbee先生担任执行副总裁、Myriad Genetics, Inc.以及TERM1 Genetics,Inc.的财务主管。Riggsbee先生目前担任CareDx,Inc.的独立董事(自2024年起)并担任审计和财务委员会主席;担任Immunovia AB的独立董事(自2025年起)并在审计和薪酬委员会任职。在其职业生涯的早期,Riggsbee先生曾在美国实验室公司、通用电气公司和毕马威会计师事务所担任财务领导职务。
R. Bryan Riggsbee joined Neogen on November 3, 2025 as Senior Vice President & Chief Financial Officer. Mr. Riggsbee oversees Neogen's global finance organization. Prior to joining Neogen, Mr. Riggsbee served as Chief Financial Officer of bioMérieux's North American business in 2025, where he was responsible for the finance organization supporting the company's diagnostics operations in the region. From 2014 to 2024, Mr. Riggsbee served as Executive Vice President, Chief Financial Officer and Treasurer of Myriad Genetics, Inc. Mr. Riggsbee currently serves as an independent director of CareDx, Inc. (since 2024), where he chairs the Audit and Finance Committee, and as an independent director of Immunovia AB (since 2025), where he serves on the Audit and Remuneration Committees. Earlier in his career, Mr. Riggsbee held finance leadership roles with Laboratory Corporation of America, GE, and KPMG.
Jennifer Evans Stacey

Jennifer Evans Stacey, Esq自2006年6月担任公司执行副总裁,总法律顾问,人力资源官和秘书,Stacey女士在2005年2月加入本公司担任执行副总裁,总法律顾问兼秘书,一直到2004年4月Stacey女士担任安万特贝林有限责任公司(Aventis Behring L.L.C)公司通信高级副总裁和法律总顾问,这是安万特公司(Aventis)的全资子公司,前身为赛诺菲 - 安万特(Sanofi-Aventis)。Stacey女士于1995年安万特灵公司(Aventis Behring)创立时担任总法律顾问职位,还担任董事会的秘书。在安万特灵公司(Aventis Behring)创立之前,Stacey女士任职于Rhone-Poulenc Rorer公司(赛诺菲 - 安万特公司的前身),首先在其位于Collegeville的总部担任国际法律顾问,然后在其位于法国巴黎的办事处担任国际法律顾问。Stacey女士在华盛顿特区的金斯伯丁公司(King & Spalding)开始了她的法律职业生涯,在那里她担任公司财务部的合伙人。Stacey女士获得普林斯顿大学(Princeton University)学士学位并获得宾夕法尼亚大学法学院(University of Pennsylvania Law School)的法学博士学位。


Jennifer Evans Stacey has served as a member of our board of directors since March of 2021. Ms. Stacey is currently Chief Legal and Compliance Officer of Galera Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. Ms. Stacey has 25 years of global senior executive experience managing public, private and non-profit companies, ranging in size from 60 to 5500 employees and primarily within the life sciences industry. Prior to Galera, Ms. Stacey served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, and before that as Senior Vice President, General Counsel, Human Resources and Secretary at Antares Pharma, Inc. Previously, Ms. Stacey served as Executive Vice President, General Counsel, Human Resources, and Secretary at Auxilium Pharmaceuticals, Inc., and as Senior Vice President, Corporate Communications, General Counsel and Secretary at Aventis Behring, LLC. She began her career in life sciences at Rhone-Poulenc Rorer, including two years in their Paris office and prior to that began her legal career at King & Spalding in Washington, DC. Ms. Stacey graduated magna cum laude with an A.B. from Princeton University and earned her J.D. from the University of Pennsylvania Law School.
Jennifer Evans Stacey, Esq自2006年6月担任公司执行副总裁,总法律顾问,人力资源官和秘书,Stacey女士在2005年2月加入本公司担任执行副总裁,总法律顾问兼秘书,一直到2004年4月Stacey女士担任安万特贝林有限责任公司(Aventis Behring L.L.C)公司通信高级副总裁和法律总顾问,这是安万特公司(Aventis)的全资子公司,前身为赛诺菲 - 安万特(Sanofi-Aventis)。Stacey女士于1995年安万特灵公司(Aventis Behring)创立时担任总法律顾问职位,还担任董事会的秘书。在安万特灵公司(Aventis Behring)创立之前,Stacey女士任职于Rhone-Poulenc Rorer公司(赛诺菲 - 安万特公司的前身),首先在其位于Collegeville的总部担任国际法律顾问,然后在其位于法国巴黎的办事处担任国际法律顾问。Stacey女士在华盛顿特区的金斯伯丁公司(King & Spalding)开始了她的法律职业生涯,在那里她担任公司财务部的合伙人。Stacey女士获得普林斯顿大学(Princeton University)学士学位并获得宾夕法尼亚大学法学院(University of Pennsylvania Law School)的法学博士学位。
Jennifer Evans Stacey has served as a member of our board of directors since March of 2021. Ms. Stacey is currently Chief Legal and Compliance Officer of Galera Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. Ms. Stacey has 25 years of global senior executive experience managing public, private and non-profit companies, ranging in size from 60 to 5500 employees and primarily within the life sciences industry. Prior to Galera, Ms. Stacey served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, and before that as Senior Vice President, General Counsel, Human Resources and Secretary at Antares Pharma, Inc. Previously, Ms. Stacey served as Executive Vice President, General Counsel, Human Resources, and Secretary at Auxilium Pharmaceuticals, Inc., and as Senior Vice President, Corporate Communications, General Counsel and Secretary at Aventis Behring, LLC. She began her career in life sciences at Rhone-Poulenc Rorer, including two years in their Paris office and prior to that began her legal career at King & Spalding in Washington, DC. Ms. Stacey graduated magna cum laude with an A.B. from Princeton University and earned her J.D. from the University of Pennsylvania Law School.